Fortune Profiles Pillsbury Client’s Development of Potentially Life-Changing ALS and Alzheimer’s Treatments

The venerable business publication’s longest feature ever focused on the company’s promising and novel new treatments for Alzheimer's, ALS, Parkinson's and a host of other neurodegenerative diseases. The social implications of the treatments the Jackson Hole, Wyo., nonprofit is working on "could be comparable to the Polio vaccine," Wetherell noted.

Wetherell began working with Dr. Cox 20 years ago when he was on the faculty at Brigham Young University. Dr. Cox went on to establish Brain Chemistry Labs, for which Pillsbury oversees the company’s large global patent portfolio.

The Fortune article details in great depth how BCL discovered what could be a novel treatment for Alzheimer's, ALS, Parkinson's and a host of other neurodegenerative diseases. While some existing medications can borrow time for patients, the diseases are mostly incurable. This treatment, which is based on a natural occurring protein building block called L-serine, could become a "tremendous breakthrough with a potentially world-changing effect," Wetherell said.